Author

Axel Dignass

EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL
EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL

Axel Dignass  et al.

THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS THROUGH WEEK 12
THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS THROUGH WEEK 12

Axel Dignass  et al.

CHARACTERISTICS OF FILGOTINIB-TREATED PATIENTS WITH ULCERATIVE COLITIS WHO ACHIEVE SUSTAINED CORTICOSTEROID-FREE REMISSION: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY
CHARACTERISTICS OF FILGOTINIB-TREATED PATIENTS WITH ULCERATIVE COLITIS WHO ACHIEVE SUSTAINED CORTICOSTEROID-FREE REMISSION: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

Axel Dignass  et al.

Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: STARDUST trial
Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: STARDUST trial

Axel Dignass  et al.

EARLY SYMPTOMATIC IMPROVEMENT WITH GUSELKUMAB INDUCTION TREATMENT IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
EARLY SYMPTOMATIC IMPROVEMENT WITH GUSELKUMAB INDUCTION TREATMENT IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY

Axel Dignass  et al.

Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS)
Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS)

Axel Dignass  et al.

IN CONTRAST TO ORAL IRON THERAPY, INTRAVENOUS IRON THERAPY IS NEITHER INFLUENCED BY, NOR DOES IT EXACERBATE, SYSTEMIC INFLAMMATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
IN CONTRAST TO ORAL IRON THERAPY, INTRAVENOUS IRON THERAPY IS NEITHER INFLUENCED BY, NOR DOES IT EXACERBATE, SYSTEMIC INFLAMMATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Axel Dignass  et al.

CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS
CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS

Axel Dignass  et al.

IMPROVEMENT IN INFLAMMATORY BIOMARKER LEVELS THROUGH WEEK 12 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS PATIENTS TREATED WITH GUSELKUMAB: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
IMPROVEMENT IN INFLAMMATORY BIOMARKER LEVELS THROUGH WEEK 12 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS PATIENTS TREATED WITH GUSELKUMAB: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY

Axel Dignass  et al.

IN CONTRAST TO FAECAL CALPROTECTIN (FC), INCREASED FAECAL APHA-1-ANTITRYPSIN (A1AT) EXCRETION IS ASSOCIATED WITH LOW THROUGH LEVELS IN PATIENTS WITH SEVERE ULCERATIVE COLITIS LACKING RESPONSE TO MONOCLONAL ANTIBODY (MAB) THERAPY
IN CONTRAST TO FAECAL CALPROTECTIN (FC), INCREASED FAECAL APHA-1-ANTITRYPSIN (A1AT) EXCRETION IS ASSOCIATED WITH LOW THROUGH LEVELS IN PATIENTS WITH SEVERE ULCERATIVE COLITIS LACKING RESPONSE TO MONOCLONAL ANTIBODY (MAB) THERAPY

Axel Dignass  et al.

TREAT-TO-TARGET MAINTENANCE EFFICACY AND PHARMACOKINETICS OF USTEKINUMAB DOSING REGIMEN UP TO WEEK 48 IN THE STARDUST TRIAL
TREAT-TO-TARGET MAINTENANCE EFFICACY AND PHARMACOKINETICS OF USTEKINUMAB DOSING REGIMEN UP TO WEEK 48 IN THE STARDUST TRIAL

Axel Dignass  et al.

USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY-OF-LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN´S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIAL
USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY-OF-LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN´S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIAL

Axel Dignass  et al.

USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS UP TO WEEK 104 OF THE STARDUST TRIAL
USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS UP TO WEEK 104 OF THE STARDUST TRIAL

Axel Dignass  et al.

PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE–RESPONSE RELATIONSHIPS OF USTEKINUMAB TREATMENT IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE WEEK 48 TREAT TO TARGET VS STANDARD OF CARE ANALYSIS OF THE STARDUST STUDY
PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE–RESPONSE RELATIONSHIPS OF USTEKINUMAB TREATMENT IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE WEEK 48 TREAT TO TARGET VS STANDARD OF CARE ANALYSIS OF THE STARDUST STUDY

Axel Dignass  et al.

PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY
PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY

Axel Dignass  et al.

THE IMPACT OF COVID-19 ON GI PRACTICE IN EUROPE AND BEYOND - A SURVEY
THE IMPACT OF COVID-19 ON GI PRACTICE IN EUROPE AND BEYOND - A SURVEY

Axel Dignass  et al.

A GLOBAL CONSENSUS ON THE DEFINITIONS, DIAGNOSIS AND MANAGEMENT OF FIBROSTENOSING SMALL BOWEL CROHN'S DISEASE
A GLOBAL CONSENSUS ON THE DEFINITIONS, DIAGNOSIS AND MANAGEMENT OF FIBROSTENOSING SMALL BOWEL CROHN'S DISEASE

Axel Dignass  et al.

HEPATIC SAFETY OF OZANIMOD IN ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS PHASE 3 TRIALS
HEPATIC SAFETY OF OZANIMOD IN ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS PHASE 3 TRIALS

Axel Dignass  et al.

CHARACTERISTICS AND REAL WORLD TREATMENT HISTORY OF PATIENTS TREATED WITH TOFACITINIB FOR ULCERATIVE COLITIS IN EUROPE
CHARACTERISTICS AND REAL WORLD TREATMENT HISTORY OF PATIENTS TREATED WITH TOFACITINIB FOR ULCERATIVE COLITIS IN EUROPE

Axel Dignass  et al.

THE EFFECT OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS AT WEEK 12 BY PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO ADVANCED THERAPY
THE EFFECT OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS AT WEEK 12 BY PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO ADVANCED THERAPY

Axel Dignass  et al.

Item 21 - 40 / 46
1
2
3